Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 11:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 7,000 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Carcinoma Clear all
Recruiting No phase listed Observational

Oncoplastic Surgery Outcomes Database

NCT07597837
View directory record Official record
Conditions
Breast Cancer
Interventions
Oncoplastic Breast Surgery
Procedure
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2045
U.S. locations
2
States / cities
Boston, Massachusetts • Melrose, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 29, 2026, 11:24 AM EDT
Recruiting Phase 2 Interventional

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

NCT03606967
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Carboplatin, Computed Tomography, Durvalumab, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Nab-paclitaxel, Personalized Synthetic Long Peptide Vaccine, Poly ICLC, Sacituzumab Govitecan, Tremelimumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
30
States / cities
Orange, California • Sacramento, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 29, 2026, 11:24 AM EDT
Terminated Phase 1 Interventional

RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery

NCT01071564
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study, Vismodegib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Baltimore, Maryland • Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases

NCT00587964
View directory record Official record
Conditions
Brain Metastasis, Bladder Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, HEENT Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Sarcoma, Testicular Cancer
Interventions
Stereotactic Radiosurgery
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Oct 29, 2026, 11:24 AM EDT
Not listed Phase 1 Interventional

Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors

NCT04450732
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor
Interventions
GQ1001
Drug
Lead sponsor
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Not applicable Interventional

Evaluation of a 3-D Tomosynthesis Mammography System Used in Conjunction With Conventional 2-D Digital Mammography

NCT00754598
View directory record Official record
Conditions
Breast Cancer
Interventions
Tomosynthesis digital mammography imaging system
Device
Lead sponsor
Hologic, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
New Haven, Connecticut • Iowa City, Iowa • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 29, 2026, 11:24 AM EDT
Terminated Phase 1 Interventional

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

NCT05069935
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
FT538, Cyclophosphamide, Fludarabine, Monoclonal antibody - Dose Escalation, Monoclonal antibody - Dose Expansion
Drug · Combination Product
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Hackensack, New Jersey • Nashville, Tennessee • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Not applicable Interventional

Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors

NCT05364450
View directory record Official record
Conditions
Breast Neoplasm, Breast Cancer, Breast Carcinoma, Malignant Neoplasm of Breast, Cancer of Breast, Mammary Neoplasms, Human, Human Mammary Carcinoma, Malignant Tumor of Breast, Mammary Cancer, Mammary Carcinoma, Human, Anxiety, Fear
Interventions
Enhanced Usual Care, Acceptance Commitment Therapy, Cognitive Behavioral Therapy
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 29, 2026, 11:24 AM EDT
Completed No phase listed Observational

Establishing an Inflammatory Breast Cancer Registry

NCT00340158
View directory record Official record
Conditions
Inflammatory Breast Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 23, 2010 · Synced Oct 29, 2026, 11:24 AM EDT
Terminated No phase listed Observational

Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer

NCT05447910
View directory record Official record
Conditions
Breast Adenocarcinoma, Invasive Breast Carcinoma, Resectable Breast Carcinoma
Interventions
Biospecimen Collection
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Not applicable Interventional

Arm Function and Quality of Life Following Mastectomy.

NCT00379106
View directory record Official record
Conditions
Breast Cancer
Interventions
Arm Exercises
Procedure
Lead sponsor
University of New Mexico
Other
Eligibility
Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 7, 2010 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 3 Interventional

Comparing RadiaPlexRx Hydrogel and Standard-of-Care for Radiation Dermatitis in Breast Cancer Patients

NCT00481884
View directory record Official record
Conditions
Radiation Dermatitis
Interventions
RadiaPlexRx Gel, Aquaphor Gel
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Oct 29, 2026, 11:24 AM EDT
Completed No phase listed Observational

Evaluating Mepitel in Post-mastectomy Patients and the Role of the Skin Microbiome in Radiation Dermatitis

NCT03519438
View directory record Official record
Conditions
Breast Cancer
Interventions
Mepitel
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 20, 2022 · Synced Oct 29, 2026, 11:24 AM EDT
Completed No phase listed Observational

Achieving Equity in Genomic Testing for Breast Cancer Through Partner-Led Strategies and Policies

NCT05916378
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 99 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 29, 2026, 11:24 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

MR Guided Focused Ultrasound Surgery in the Treatment of Breast Fibroadenomas

NCT00147108
View directory record Official record
Conditions
Breast Fibroadenoma
Interventions
ExAblate 2000
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
4
States / cities
Boca Raton, Florida • Boston, Massachusetts • Voorhees Township, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2012 · Synced Oct 29, 2026, 11:24 AM EDT
Not listed Not applicable Interventional

Post-Mastectomy Surveillance to Detect Recurrence in Breast Cancer Patients

NCT02688725
View directory record Official record
Conditions
Breast Cancer
Interventions
post mastectomy ultrasound
Device
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Everett, Washington
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 29, 2026, 11:24 AM EDT
Terminated Phase 1 Interventional

Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

NCT06714617
View directory record Official record
Conditions
Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer, Unresectable Breast Carcinoma, Her2-Positive, HER2 Gene Mutation, Gastroesophageal-junction Cancer, Non Small Cell Lung Cancer, Endometrial Neoplasms, Peritoneal Cancer, Fallopian Tube Cancer, Ovarian Cancer, Urothelial Carcinoma Bladder, Solid Tumor, Adult, Gastric Cancer
Interventions
BL-M17D1
Drug
Lead sponsor
SystImmune Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Denver, Colorado • New Haven, Connecticut • Lake Mary, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Not applicable Interventional

Comparison of MRI and CEDM to Evaluate Treatment Response Before Surgery

NCT03070340
View directory record Official record
Conditions
Breast Cancer
Interventions
Breast Magnetic Resonance Imaging (MRI), Contrast Enhanced Mammography (CEDM)
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Female only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Montvale, New Jersey • Commack, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Oct 29, 2026, 11:24 AM EDT
Recruiting Not applicable Interventional

Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer

NCT06534125
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Interventions
Acupressure Therapy, Acupuncture Therapy, Aromatase Inhibition Therapy, Discussion, Survey Administration
Procedure · Device · Drug + 1 more
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

NCT00834678
View directory record Official record
Conditions
Breast Cancer
Interventions
bendamustine, erlotinib, Maintenance erlotinib
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 29, 2026, 11:24 AM EDT
Recruiting No phase listed Observational

Collection of Specimens and Clinical Data for Patients With Recurrent or Metastatic Breast Cancer or Male Breast Cancer

NCT06217874
View directory record Official record
Conditions
Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2034
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 4 Interventional

A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment

NCT00190697
View directory record Official record
Conditions
Breast Cancer, Endometrial Cancer, Ovarian Cancer
Interventions
arzoxifene
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 25, 2007 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Pregabalin in Treating Women With Hot Flashes

NCT00702949
View directory record Official record
Conditions
Breast Cancer, Hot Flashes
Interventions
pregabalin, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
209
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 135 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mammogram Mail- and Phone-based Interventions

NCT05853848
View directory record Official record
Conditions
Breast Cancer
Interventions
Postcard, Letter, Auto-dialer, Live call
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
51 Years to 74 Years · Female only
Enrollment
14,386 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Oct 29, 2026, 11:24 AM EDT